Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.44 |
| ▸ | ITGAV | P06756 | 19/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6474022 | 0.96 | ITGB3 (0.43) | ITGB3ITGAVITGA2B | |
| SCHEMBL6480964 | 0.92 | ITGB3 (0.38) | ITGB3ITGAVITGA2B | |
| SCHEMBL6481534 | 0.91 | ITGB3 (0.43) | ITGB3ITGAVITGA2B | |
| SCHEMBL6481186 | 0.87 | ITGB3 (0.37) | ITGB3ITGAVITGA2B | |
| SCHEMBL6476022 | 0.86 | ITGB3 (0.46) | ITGB3ITGAVITGA2B | |
| SCHEMBL6481139 | 0.83 | SYK (0.38) | ITGB3ITGAVITGA2B | |
| SCHEMBL6474857 | 0.83 | ITGB3 (0.43) | ITGB3ITGAVITGA2B | |
| SCHEMBL8039403 | 0.82 | ITGB3 (0.41) | ITGB3ITGAVITGA2B | |
| SCHEMBL6474654 | 0.80 | ITGB3 (0.43) | ITGB3ITGAVITGA2B | |
| SCHEMBL6474646 | 0.79 | SYK (0.40) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0854140-B1 | Vitronectin receptor antagonists, their production and their use | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-11-06 | — | — | EP | disclosed |
| US-6867208-B2 | Vitronectin receptor antagonists, their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 2005-03-15 | — | — | US | disclosed |
| US-20030027807-A1 | Vitronectin receptor antagonists, their preparation and their use | GENENTECH, INC. AND HOECHST AKTIENGESELLSCHAFT | 2003-02-06 | — | — | US | disclosed |
| US-6387895-B1 | BONE DISORDERS; CARDIOVASCULAR DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-05-14 | — | — | US | disclosed |
| US-6207663-B1 | AS INHIBITORS OF BONE RESORPTION, TUMOR GROWTH, TUMOR METASTASIS, OR INFLAMMATION, OR FOR THE TREATMENT OR PROPHYLAXIS OF CARDIOVASCULAR DISORDERS, NEPHROPATHIES OR RETINOPATHIES | HOECHST ATKIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
| US-6011045-A | Vitronectin receptor antagonists, their preparation and their use | HOECHST AKTIENGESELLSCHAFT | 2000-01-04 | — | — | US | disclosed |
| EP-0854140-A2 | Vitronectin receptor antagonists, their production and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027807-A1 | Vitronectin receptor antagonists, their preparation and their use | ADGRF1, ADGRE5, BSG | ITGB3 173/4885ITGAV 145/4885ITGA2B 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.